Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
Healthcare
$20.94 +1.46%
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
52W Low $15.60High $36.44
Volume 4.21M
Average 2.11M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$345.10M
FY 2025 · Annual
Investing Cash Flow
-$121.44M
FY 2025 · Annual
Financing Cash Flow
$478.05M
FY 2025 · Annual
+6079.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (370.64M) | (289.09M) | (132.53M) | (376.74M) | (79.99M) |
| Depreciation & Amortization | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 43.57M | 84.32M | 98.65M | 120.66M | 94.24M |
| Change in Working Capital | 111.25M | 251.63M | (116.46M) | (110.22M) | (131.02M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | 0 | (300M) | 0 | 0 | 0 |
| Accounts Payables | 818K | 2.37M | (7.58M) | 1.81M | 6.04M |
| Other Working Capital | 410.44M | 249.26M | (108.88M) | (112.03M) | (137.06M) |
| Other Non-Cash Items | 142.1M | (38.48M) | (18.87M) | (2.87M) | (250.63M) |
| Operating Cash Flow | (66.27M) | 22.53M | (149.2M) | (347.25M) | (345.1M) |
| Capital Expenditures | (46.81M) | (48.95M) | (33.73M) | (8.95M) | (14.95M) |
| Acquisitions (Net) | 620K | 412.39M | 0 | 0 | (78K) |
| Purchases of Investments | (777.22M) | (1.62B) | (984.34M) | (486.44M) | (1.21B) |
| Sales of Investments | 529.27M | 1.2B | 1.09B | 680.39M | 848.63M |
| Other Investing Activities | 0 | (412.39M) | 0 | 0 | 254.75M |
| Investing Cash Flow | (294.14M) | (461.34M) | 71.84M | 185.01M | (121.44M) |
| Debt Repayment | (2.12M) | (2.29M) | (2.25M) | (485K) | 0 |
| Common Stock Issued | 757.45M | 108.26M | 270.17M | 8.22M | 478.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 810K | 5.62M | 8.53M | 0 | 0 |
| Financing Cash Flow | 756.14M | 111.59M | 276.45M | 7.74M | 478.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 395.73M | (327.22M) | 199.09M | (154.5M) | 11.51M |
| Free Cash Flow | (113.08M) | (26.42M) | (182.93M) | (356.19M) | (360.05M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$80.0M
+ D&A$22.3M
+ Stock-Based Comp$94.2M
+ Deferred Tax$0
- Working Capital-$131.0M
- Other Non-Cash-$250.6M
= Operating Cash Flow-$345.1M
- Capex-$14.9M
= Free Cash Flow-$360.0M
Analysis
FY2025 free cash flow is -$360.0M. FCF conversion is 450.1% of net income. Operating cash flow was -$345.1M, with capex of -$14.9M. The largest bridge item is Other Non-Cash at -$250.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
Does BEAM generate free cash flow?
Beam Therapeutics Inc. (BEAM) generated -$360.05M of free cash flow in fiscal 2025.
How much operating cash flow does BEAM produce?
Operating cash flow was -$345.10M, before capital expenditures of $14.95M.
Continue the stock analysis
Jump to another research area for this company.